<DOC>
	<DOCNO>NCT02562768</DOCNO>
	<brief_summary>This two-part study evaluate safe LY3154207 effect body . Part A include healthy participant . Each participant receive daily dos LY3154207 placebo 14 day . Part A last approximately 4 week include 17 day stay clinical research unit ( CRU ) follow-up . Part B contingent result Part A . Part B include participant Parkinson 's disease . Each participant receive daily dos LY3154207 placebo 14 day . Part B last approximately 4 week include 17 day stay CRU follow-up . Both Part A Part B require screening within 30 day prior start study .</brief_summary>
	<brief_title>A Study LY3154207 Healthy Participants Participants With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Part A : Overtly healthy male female , determine medical history physical examination Female participant childbearing potential Part B : Have clinical diagnosis idiopathic Parkinson 's disease least 1 year stable medication least 4 week Part A B Are reliable willing make available duration study willing follow study procedure Have give write informed consent Have body mass index ( BMI ) 18.0 29.9 kilogram per square meter ( kg/mÂ² ) Have participate , last 30 day , clinical trial involve investigational product Have significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological neurological disorder capable significantly alter absorption , metabolism elimination drug ; constitute risk take study medication ; interfere interpretation study data</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>